Uli Hacksell – CEO & President, Medivir, Sweden
Medivir is a Swedish biotech company focusing on the development and commercialization of innovative treatments for cancers of high unmet medical need. Last October, Dr Uli Hacksell was appointed CEO…
Medivir, founded in 1988 and listed on the Stockholm Stock Exchange in 1996, is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer, bringing together a unique combination of clinical development skills, a collaborative culture and an extensive industry experience, with a balanced project portfolio. Medivir has collaborated with Eli Lilly, Wellcome, Abbott, and Janssen. Medivir is led by CEO Uli Hacksell, appointed in 2015.
Address: Box 1086, SE-141 22 Huddinge, Sweden
Tel: +46 (0)8 546 831 00
Email: info@medivir.com
Website: https://www.medivir.com/
Medivir is a Swedish biotech company focusing on the development and commercialization of innovative treatments for cancers of high unmet medical need. Last October, Dr Uli Hacksell was appointed CEO…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for…
Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
Hong Kong is at a strategic inflection point as it seeks to redefine its role in global life sciences through regulatory credibility, institutional design, and long-term positioning between China and…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
See our Cookie Privacy Policy Here
